Veterans Medical Cannabis Access — Federal Policy, VA Benefits & State Programs

Executive Summary

The U.S. House of Representatives approved a fiscal year 2027 appropriations bill in May 2026 that would grant military veterans access to medical cannabis through the Department of Veterans Affairs (VA) for the first time in federal history. The provision, embedded in the Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, now advances to the Senate where its fate remains uncertain. If enacted, the measure would allow VA physicians to recommend medical cannabis to veterans in states with legal medical marijuana programs, ending a decades-long prohibition that has forced an estimated 2.9 million veterans to navigate state-legal cannabis programs without federal healthcare support. The House vote represents the culmination of more than fifteen years of advocacy by veterans service organizations, cannabis reform groups, and bipartisan congressional allies who argue that VA restrictions have denied veterans access to a treatment option many credit with managing post-traumatic stress disorder (PTSD), chronic pain, and other service-connected conditions. The provision does not require the VA to dispense cannabis directly, but removes federal barriers preventing VA doctors from discussing and recommending cannabis as a treatment option in the 38 states plus the District of Columbia where medical marijuana is legal.

Why This Matters

More than 18 million living U.S. military veterans face a healthcare paradox: they can legally access medical cannabis in most states but cannot discuss it with their federal VA doctors without risking loss of benefits or prescription medications. The VA operates the largest integrated healthcare system in the United States, serving 9.1 million enrolled veterans annually through 171 medical centers and 1,113 outpatient facilities. Veterans experience PTSD at rates five times higher than the general population, with Department of Veterans Affairs data showing 23 percent of post-9/11 veterans screening positive for the condition. Chronic pain affects an estimated 50 percent of veterans seeking VA care, double the rate in civilian populations. Opioid-related overdose deaths among veterans reached 2,087 in 2023 according to VA mortality data, representing a 45 percent increase since 2019. Veterans currently spend an estimated $1.8 billion annually out-of-pocket on state-legal medical cannabis, according to a 2025 analysis by the Veterans Cannabis Project, a nonprofit advocacy organization. These costs are not reimbursable through VA healthcare benefits or private insurance due to cannabis's Schedule I classification under the Controlled Substances Act (21 U.S.C. § 812). The financial burden falls disproportionately on disabled veterans living on fixed VA disability compensation, which ranges from $165 to $3,737 monthly depending on disability rating. The policy gap affects military families and caregivers who report confusion about whether discussing cannabis use with VA providers could jeopardize access to other medications. Current VA Directive 1315 instructs providers to document cannabis use in medical records but prohibits recommendations or referrals to state programs. Veterans in states like California, Colorado, and Oregon report avoiding honest disclosure of cannabis use to VA doctors, creating dangerous gaps in medication interaction screening and care coordination.

Background and History

The conflict between federal cannabis prohibition and veterans' healthcare needs has evolved over three decades, shaped by changing state laws, congressional advocacy, and the VA's institutional resistance to cannabis policy reform.

1996-2009: State Medical Marijuana Emerges

California voters approved Proposition 215 in November 1996, establishing the nation's first state-legal medical marijuana program. The Compassionate Use Act explicitly listed conditions common among veterans including chronic pain and PTSD as qualifying conditions. Within five years, eight additional states enacted medical cannabis laws, but the VA maintained absolute prohibition on any cannabis-related services. The VA's position hardened in 2002 when Deputy Under Secretary for Health Robert Roswell issued a memorandum stating that VA physicians could not recommend medical marijuana under any circumstances due to federal law. The policy remained unchanged even as Iraq and Afghanistan war veterans began returning with high rates of PTSD and traumatic brain injury (TBI). By 2009, twelve states had medical marijuana programs, yet VA Directive 2009-053 reiterated that veterans who tested positive for cannabis could be denied pain medication prescriptions including opioids.

2010-2014: First Congressional Efforts

Representative Earl Blumenauer of Oregon introduced the first veterans medical cannabis amendment to a VA appropriations bill in July 2010. The measure would have allowed VA doctors in states with medical marijuana laws to recommend cannabis to veterans with PTSD, chronic pain, or other qualifying conditions. The House defeated the amendment 194-233, with opposition led by the Veterans Affairs Committee chairman who cited federal law conflicts. Iraq Veterans of America and Veterans of Foreign Wars began surveying members about cannabis use in 2011, finding that 22 percent of post-9/11 veterans reported using cannabis to manage service-connected conditions. The American Legion, the nation's largest veterans service organization with 1.8 million members, adopted Resolution 11 in August 2016 calling on Congress to remove cannabis from Schedule I and allow VA research into therapeutic applications for veterans.

2015-2017: Bipartisan Momentum Builds

The Senate Appropriations Committee approved language in June 2015 allowing VA physicians to recommend medical marijuana in states where legal, marking the first time either chamber advanced such a provision. The language did not survive House-Senate conference negotiations, but demonstrated growing bipartisan support. Senator Steve Daines of Montana and Senator Jeff Merkley of Oregon led the effort, citing constituent veterans who reported cannabis helped reduce opioid dependence. The VA issued VHA Directive 1315 in November 2017, clarifying that veterans would not be denied VA services solely for participating in state marijuana programs, but maintaining the prohibition on VA physician recommendations. The directive instructed providers to document cannabis use and adjust treatment plans accordingly, but stopped short of allowing active recommendations. Veterans advocates criticized the policy as inadequate, noting it still prevented VA doctors from providing guidance on dosing, strain selection, or potential drug interactions.

2018-2021: Research Barriers and Legislative Stalemate

Congress appropriated $3 million in fiscal year 2018 for VA research into cannabis for chronic pain and PTSD, but the VA did not initiate any clinical trials due to Drug Enforcement Administration (DEA) licensing requirements and limited access to research-grade cannabis. The National Institute on Drug Abuse (NIDA) maintained a monopoly on federally legal cannabis cultivation for research at the University of Mississippi, producing material that veterans and researchers criticized as lower quality than state-legal products. The House passed veterans medical cannabis provisions in appropriations bills in 2019, 2020, and 2021, but the Senate removed the language each year during conference committee negotiations. Senator John Boozman of Arkansas, ranking member of the Senate Veterans Affairs Committee, consistently opposed the measures, arguing they conflicted with federal law and could jeopardize VA physicians' DEA licenses to prescribe controlled substances.

2022-2024: State Expansion and Federal Gridlock

By January 2022, 37 states had enacted medical cannabis programs, with PTSD listed as a qualifying condition in 34 states. Veterans comprised between 15 and 30 percent of registered medical marijuana patients in states that tracked veteran status, according to data compiled by the Marijuana Policy Project. Mississippi became the 38th medical cannabis state in February 2022, leaving only twelve states without legal access programs. The VA Medicinal Cannabis Research Act, introduced by Representative Lou Correa of California in March 2023, would have required the VA to conduct or support clinical trials examining cannabis for PTSD, chronic pain, and other conditions affecting veterans. The bill gained 68 cosponsors but did not receive a committee vote. Parallel legislation in the Senate, sponsored by Senator Jon Tester of Montana, similarly stalled despite support from major veterans service organizations including the American Legion, AMVETS, and Iraq and Afghanistan Veterans of America.

2025-2026: Appropriations Strategy Succeeds

The House Appropriations Committee approved the fiscal year 2026 Military Construction-VA bill in June 2025 with a provision allowing VA physicians to discuss and recommend medical cannabis in legal states. The full House passed the measure 224-206 in July 2025, but the Senate removed the language before final passage. Advocates shifted strategy, building support among Senate appropriators and emphasizing the provision's limited scope—it would not require the VA to dispense cannabis or change federal law, only remove barriers to physician recommendations. The House passed the fiscal year 2027 appropriations bill on May 20, 2026, retaining the medical cannabis access provision with stronger support than previous years. The vote of 238-192 included 18 Republican supporters, reflecting growing recognition of veterans' demands for cannabis access and frustration with opioid-centered pain management. The bill now advances to the Senate Appropriations Committee, where Chairman Patty Murray of Washington has indicated openness to the provision if it includes safeguards for VA physicians.

Key Players

Department of Veterans Affairs

The VA operates under Title 38 of the United States Code and serves as the federal government's second-largest cabinet department with 412,000 employees and a fiscal year 2026 budget of $369 billion. The Veterans Health Administration (VHA), the VA's healthcare delivery arm, maintains the prohibition on cannabis recommendations through VHA Directive 1315. VA Secretary Denis McDonough has not publicly supported changing the policy, citing federal law constraints and concerns about evidence quality. The VA's Office of Research and Development has conducted no clinical trials on cannabis despite congressional appropriations, attributing delays to DEA licensing requirements and institutional review board concerns.

Veterans Service Organizations

The American Legion adopted Resolution 11 in August 2016, becoming the first major veterans organization to call for cannabis rescheduling and VA access. The organization's 1.8 million members include veterans from World War II through current conflicts. Iraq and Afghanistan Veterans of America (IAVA), representing 425,000 post-9/11 veterans, made medical cannabis access a top legislative priority in 2024 and 2025. Veterans of Foreign Wars (VFW), with 1.4 million members, adopted a resolution in July 2023 supporting veterans' access to medical cannabis in legal states. AMVETS, Disabled American Veterans, and Paralyzed Veterans of America have endorsed similar positions.

Congressional Champions

Representative Earl Blumenauer of Oregon introduced the first veterans cannabis amendment in 2010 and has led House efforts for sixteen years. Representative Lou Correa of California chairs the House Veterans Affairs Subcommittee on Health and sponsored standalone research legislation. Senator Jon Tester of Montana, a senior member of the Senate Veterans Affairs Committee, has introduced companion legislation in multiple sessions. Senator Steve Daines of Montana and Senator Jeff Merkley of Oregon led the first successful Senate committee vote in 2015. Representative Matt Gaetz of Florida and Representative Barbara Lee of California have championed the issue from opposite ends of the political spectrum, demonstrating bipartisan appeal.

Advocacy Organizations

NORML (National Organization for the Reform of Marijuana Laws) has tracked veterans cannabis legislation since 2010 and coordinates advocacy campaigns with veterans groups. The Veterans Cannabis Project, founded in 2018, focuses exclusively on veterans' access issues and has organized lobby days bringing veterans to Capitol Hill. Drug Policy Alliance provides policy analysis and legal research supporting veterans' access arguments. Americans for Safe Access maintains a veterans-specific program tracking state-level qualifying conditions and access barriers.

Opposition

Smart Approaches to Marijuana (SAM), led by former Representative Patrick Kennedy, opposes the provision arguing that cannabis lacks FDA approval and could harm veterans. The organization has lobbied Senate appropriators to remove the language. Some Veterans Affairs Committee members have expressed concerns about liability for VA physicians and potential conflicts with DEA regulations governing controlled substance prescriptions. The Department of Justice has not taken a formal position but has historically opposed appropriations riders that conflict with Controlled Substances Act enforcement.

Legal and Regulatory Framework

The conflict between federal cannabis prohibition and state medical marijuana programs creates a complex legal environment that affects veterans' healthcare access, physician liability, and federal benefits eligibility. The Controlled Substances Act (21 U.S.C. § 801 et seq.), enacted in 1970, classifies cannabis as a Schedule I controlled substance alongside heroin and LSD. Schedule I designation requires findings that a substance has high abuse potential, no currently accepted medical use, and lacks accepted safety for use under medical supervision. The DEA maintains this classification despite 38 states establishing medical cannabis programs and extensive clinical research demonstrating therapeutic applications. Federal physicians, including VA doctors, obtain DEA registration under 21 U.S.C. § 823 to prescribe controlled substances. The DEA has interpreted federal law to prohibit registered practitioners from recommending Schedule I substances, even in states where legal. VA physicians who recommend cannabis could theoretically face DEA license revocation, though no such enforcement action has occurred against state-licensed physicians in medical marijuana states since the Rohrabacher-Farr amendment (now Rohrabacher-Blumenauer) prohibited Justice Department interference with state programs in 2014. Title 38 U.S.C. § 7301 grants the VA Secretary authority to prescribe regulations for VA healthcare delivery. VHA Directive 1315, issued November 2017, states that veterans participating in state marijuana programs will not be denied VA services but prohibits VA providers from recommending participation or completing state program forms. The directive requires documentation of cannabis use in medical records and instructs providers to adjust treatment plans for potential drug interactions. The Supremacy Clause (U.S. Constitution Article VI, Clause 2) establishes that federal law preempts conflicting state law. However, the anti-commandeering doctrine, affirmed in Printz v. United States, 521 U.S. 898 (1997), prevents the federal government from requiring state officials to enforce federal law. This constitutional framework allows states to establish marijuana programs without violating federal law, while federal agencies remain bound by the Controlled Substances Act. The fiscal year 2027 appropriations provision would not change the Controlled Substances Act or require the DEA to modify physician registration requirements. Instead, it would prohibit the VA from using appropriated funds to enforce the recommendation prohibition in states with legal medical cannabis programs. This approach mirrors the Rohrabacher-Blumenauer amendment, which has successfully protected state programs from federal interference since 2014 through the appropriations process rather than statutory reform.

State-by-State Breakdown

Veterans' ability to access medical cannabis varies dramatically across states, with qualifying conditions, registration requirements, and costs creating a patchwork of access barriers even where programs exist.

California

California operates the nation's oldest medical cannabis program under the Compassionate Use Act of 1996 and the Medical and Regulatory Safety Act (MCRSA). PTSD became an explicitly listed qualifying condition in 2017. Veterans pay $100 for physician recommendations valid for one year, with no state registration required. The state does not track veteran participation, but industry estimates suggest 200,000 to 300,000 veterans access the program annually. Possession limits allow 8 ounces of dried cannabis and cultivation of 6 mature plants. VA facilities in Los Angeles, San Diego, and San Francisco serve large veteran populations who report using cannabis for PTSD, chronic pain, and sleep disorders.

Colorado

Colorado's medical marijuana program, established by Amendment 20 in 2000, lists PTSD as a qualifying condition added in 2017 following advocacy by veterans groups. The state charges $15 for veteran medical marijuana cards, reduced from the standard $100 fee. As of January 2026, 8,347 veterans held active registrations out of 77,209 total patients. Possession limits allow 2 ounces of dried cannabis and cultivation of 6 plants. The Denver VA Medical Center serves 85,000 enrolled veterans, many of whom report using cannabis alongside or instead of prescribed opioids for pain management.

Florida

Florida's medical marijuana program, authorized by Amendment 2 in 2016, includes PTSD as a qualifying condition. The state charges $75 for patient registration valid for one year, with physician recommendations costing $150 to $300. Florida does not offer veteran discounts, but some physicians provide reduced fees for military veterans. The state reported 52,000 veterans among 873,000 registered patients as of March 2026, representing 6 percent of participants. Possession limits restrict patients to a 35-day supply determined by recommending physicians, typically 2.5 ounces of smokable cannabis. The James A. Haley Veterans' Hospital in Tampa serves 140,000 veterans in a state with 1.5 million veteran residents.

Illinois

Illinois established a medical cannabis pilot program in 2014 and made it permanent in 2019. PTSD qualifies automatically, and the state offers a reduced $10 registration fee for veterans compared to $100 for non-veterans. As of December 2025, 14,200 veterans held active registrations out of 156,000 total patients. Possession limits allow 2.5 ounces every 14 days. The Jesse Brown VA Medical Center in Chicago serves 60,000 veterans, with staff reporting frequent questions about cannabis interactions with prescribed medications that physicians cannot answer due to federal restrictions.

New York

New York's medical marijuana program, established in 2014 and significantly expanded in 2023, includes PTSD and chronic pain as qualifying conditions. The state eliminated registration fees in 2023, removing a barrier that previously cost veterans $50 annually. Veteran participation data is not publicly reported, but the state's 230,000 registered patients include an estimated 25,000 to 35,000 veterans based on demographic surveys. Possession limits allow a 60-day supply determined by certifying practitioners. The Manhattan VA Medical Center and 11 other VA facilities in New York serve 220,000 veterans who cannot receive cannabis guidance from federal providers.

Ohio

Ohio's Medical Marijuana Control Program, launched in 2019, lists PTSD and chronic pain as qualifying conditions. The state charges $50 for patient registration, with no veteran discount. As of February 2026, 7,800 veterans held active registrations out of 142,000 total patients. Possession limits allow a 90-day supply based on physician recommendations, typically 8 ounces. The Dayton VA Medical Center serves 50,000 veterans in a state with 730,000 veteran residents, many of whom report confusion about whether discussing cannabis use could affect opioid prescriptions.

Texas

Texas operates the Compassionate Use Program, one of the nation's most restrictive medical cannabis programs. Only low-THC cannabis (0.5 percent THC or less) qualifies, and PTSD became a qualifying condition in 2019. Veterans must obtain prescriptions from registered physicians, costing $200 to $400, and register with the state at no charge. As of January 2026, only 2,100 veterans participated out of 1.6 million Texas veteran residents. The restrictive program has prompted veterans advocates to seek federal intervention as state reform efforts have stalled. VA facilities in Houston, San Antonio, and Dallas serve 180,000 veterans who lack meaningful state-legal access.

States Without Medical Cannabis Programs

Twelve states maintain complete prohibition: Idaho, Kansas, Wyoming, Nebraska, Iowa, Wisconsin, Indiana, Kentucky, Tennessee, South Carolina, Georgia, and North Carolina. These states are home to 2.8 million veterans who have no legal access to medical cannabis. Veterans in these states report traveling to neighboring states with medical programs or using cannabis illegally, risking state criminal charges and potential federal benefits complications.

Market and Business Implications

Veterans represent a significant and underserved segment of the medical cannabis market, with unique needs that could reshape product development, retail strategies, and industry economics if federal access barriers fall. The medical cannabis industry generated $8.7 billion in sales in 2025 according to BDSA analytics, with veterans estimated to comprise 12 to 18 percent of medical marijuana patients in states that track demographics. If VA physicians could recommend cannabis, industry analysts project 800,000 to 1.2 million additional veterans would enter state programs within three years, adding $1.4 to $2.1 billion in annual sales. Multi-state operators (MSOs) including Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs have developed veteran-focused initiatives offering 10 to 25 percent discounts on medical cannabis purchases. These programs currently serve veterans who obtain recommendations from state-licensed physicians, but companies anticipate expanded participation if VA doctors can recommend treatment. Trulieve operates 191 dispensaries and reported that 8 percent of medical sales in 2025 went to customers using veteran discounts, representing $47 million in revenue. Product development has responded to veteran preferences for high-CBD, low-THC formulations for daytime pain management and higher-THC products for sleep and PTSD symptoms. Strains including Northern Lights, Granddaddy Purple, and ACDC have gained popularity among veteran patients for reported efficacy in managing anxiety and pain. Terpene profiles rich in myrcene and linalool are marketed for calming effects, though clinical evidence remains limited. The Internal Revenue Code Section 280E prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses, creating effective tax rates of 70 to 85 percent for cannabis companies. Veterans' access expansion would not change 280E unless Congress enacts broader reform, but increased medical sales could improve companies' ability to demonstrate state-legal compliance and potentially support future tax relief arguments. Investment in cannabis companies has declined 60 percent since 2021 peaks, with institutional investors citing federal illegality and banking restrictions under the Bank Secrecy Act. Veterans' access provisions in appropriations bills signal potential federal policy evolution, which some analysts believe could restore investor confidence and increase capital availability for medical-focused operators. Wholesale cannabis prices have fallen 40 to 60 percent in mature markets since 2022 due to oversupply, but medical programs maintain price premiums of 15 to 30 percent over adult-use products due to lower tax rates and higher quality standards. Veterans entering medical programs would likely purchase premium products, supporting margins for cultivators and processors focused on medical markets.

What Experts Say

Medical researchers, veterans advocates, and policy analysts offer diverging perspectives on the evidence supporting cannabis for veteran populations and the implications of VA access. Dr. Sue Sisley, a physician and president of the Scottsdale Research Institute, has conducted FDA-approved clinical trials on cannabis for PTSD in veterans. According to her published research in the Journal of Psychopharmacology, veterans using whole-plant cannabis showed greater PTSD symptom reduction compared to placebo, though sample sizes remained small. She has stated that VA restrictions prevent meaningful research collaboration and limit veterans' access to potentially beneficial treatments. The American Legion's position, articulated in Resolution 11, emphasizes that veterans should have the same legal access to medical treatments as civilians in their states. The organization has noted that federal prohibition forces veterans to choose between VA healthcare and state-legal cannabis, creating unnecessary barriers for those who have served the nation. Dr. Marcel Bonn-Miller, an adjunct professor at the University of Pennsylvania Perelman School of Medicine, has researched cannabis for PTSD and published findings showing that some veterans report symptom relief, but that product quality varies significantly in state markets. His analysis of commercially available cannabis products found that 26 percent were mislabeled for THC or CBD content, raising safety concerns for veterans self-medicating without physician guidance. Iraq and Afghanistan Veterans of America has emphasized that the current policy creates dangerous information gaps, with veterans unable to discuss cannabis use with VA doctors who manage their other medications. The organization's surveys show that 39 percent of members who use cannabis have not disclosed this to VA providers due to fear of losing prescription medications or facing stigma. The Congressional Research Service issued a report in March 2025 analyzing legal frameworks for VA cannabis recommendations, concluding that appropriations language could authorize the practice without violating the Controlled Substances Act, similar to how the Rohrabacher-Blumenauer amendment protects state programs from federal interference. The analysis noted that VA physicians would still face DEA registration risks unless the agency issued clarifying guidance. Dr. Paula Schnurr, executive director of the VA's National Center for PTSD, has stated that while some veterans report benefits from cannabis, the VA cannot recommend treatments lacking FDA approval and robust clinical evidence. She has called for expanded research to determine efficacy, optimal dosing, and potential risks including cannabis use disorder. The Veterans Cannabis Project has documented cases of veterans reducing opioid use after accessing medical marijuana, citing this as evidence that cannabis could address the veteran opioid crisis. The organization's data, based on surveys of 2,400 veteran cannabis users, found that 74 percent reported reducing or eliminating opioid medications after beginning cannabis treatment.

What's Next

The fiscal year 2027 appropriations bill faces critical decision points in the Senate over the next four months, with the provision's fate depending on committee negotiations, floor amendments, and conference committee dynamics. The Senate Appropriations Committee is expected to begin markup of the Military Construction-VA bill in June 2026. Chairman Patty Murray of Washington has indicated openness to veterans' cannabis access provisions if they include protections for VA physicians and clear limitations on VA liability. Ranking Member Susan Collins of Maine has not publicly stated a position but has supported medical marijuana access in her state. If the Senate committee retains the provision, the full Senate could vote on the appropriations bill in July 2026. Floor amendments could strengthen or weaken the language, with potential modifications including requirements for VA physician training on cannabis interactions, limitations to specific conditions like PTSD and chronic pain, or sunset clauses requiring reauthorization after two years. The House and Senate must reconcile differences in a conference committee, likely in August or September 2026 before the fiscal year begins October 1, 2026. Previous years have seen veterans cannabis provisions removed during conference negotiations, but advocates believe stronger House support and growing Senate openness improve prospects for retention in the final bill. If enacted, the VA would have 90 to 180 days to implement the provision through updated directives and physician guidance. Implementation challenges include developing protocols for cannabis recommendations, training physicians on state program requirements, and establishing documentation standards that protect veterans from benefits complications. The DEA's ongoing rescheduling review, initiated in August 2023, could move cannabis to Schedule III by late 2026 or early 2027 following completion of the notice and proposed rulemaking (NPRM) process and administrative law judge (ALJ) review. Rescheduling to Schedule III would not automatically authorize VA recommendations but would eliminate the theoretical DEA license revocation risk for physicians, potentially easing VA implementation. Parallel legislative efforts continue, with the VA Medicinal Cannabis Research Act expected for reintroduction in the 119th Congress. Standalone legislation faces longer odds than appropriations riders but could provide more comprehensive reform including research mandates and explicit statutory authorization for VA recommendations. Veterans service organizations plan coordinated advocacy campaigns targeting Senate offices in June 2026, bringing veterans to Capitol Hill to share personal experiences with cannabis treatment and current access barriers. The American Legion, IAVA, and VFW have committed resources to support the provision's retention through the appropriations process. State-level developments could influence federal action, with Kentucky and North Carolina considering medical cannabis legislation in 2026 that would expand the number of states where veterans could access programs if VA recommendations become authorized.

Further Reading

• VHA Directive 1315: Access to Clinical Programs for Veterans Participating in State-Approved Marijuana Programs (November 2017) - https://www.va.gov/vhapublications/ViewPublication.asp?pub_ID=5527
• Controlled Substances Act, 21 U.S.C. § 801 et seq. - https://www.deadiversion.usdoj.gov/21cfr/21usc/
• American Legion Resolution 11: Medical Cannabis Research (August 2016) - https://www.legion.org/resolutions/medical-cannabis
• Congressional Research Service: Veterans and Medical Marijuana (March 2025) - https://crsreports.congress.gov
• Department of Veterans Affairs: Veterans Health Administration - https://www.va.gov/health/
• Iraq and Afghanistan Veterans of America: Policy Priorities - https://iava.org/policy/
• NORML: Veterans and Medical Marijuana - https://norml.org/marijuana/veterans/
• Veterans Cannabis Project - https://www.veteranscannabisproject.org/
• National Center for PTSD: Cannabis and PTSD - https://www.ptsd.va.gov/understand/related/cannabis_use.asp
• BDSA: Medical Cannabis Market Analysis (2025) - https://www.bdsa.com/

Update — May 26, 2026: House Approves VA Funding Bill With Medical Cannabis Access Provision

The U.S. House of Representatives approved a fiscal year 2027 Military Construction and Veterans Affairs appropriations bill that includes language allowing VA physicians to recommend medical cannabis to veterans in states where it is legal. The provision, which has appeared in various forms in previous congressional sessions, passed as part of the broader $167.6 billion funding package that now advances to the Senate for consideration.

The medical cannabis language prohibits the VA from denying veterans benefits or services solely because they participate in state-approved medical marijuana programs, according to the bill text. VA doctors in the 38 states with legal medical cannabis programs would be authorized to discuss cannabis as a treatment option and provide recommendations, though the department would not dispense or pay for the substance due to federal Schedule I restrictions. Veterans currently risk losing pain medication prescriptions or facing other penalties if they test positive for cannabis metabolites.

The House approved the measure by a vote of 229 to 195, with bipartisan support from veterans' advocacy groups including the American Legion and Veterans of Foreign Wars. Both organizations have endorsed medical cannabis access for years, citing the estimated 6,200 veteran suicides annually and evidence suggesting cannabis may reduce opioid dependence among former service members. The Senate Appropriations Committee has not yet scheduled markup of its companion bill.

This development matters because VA policy changes require either legislative action or agency rulemaking—administrative guidance alone cannot override the Controlled Substances Act. If the Senate includes identical language and the bill becomes law, it would represent the first statutory authorization for VA physicians to engage with state medical cannabis programs, potentially affecting care for the 9 million veterans enrolled in VA healthcare. The provision does not reschedule cannabis or create federal reimbursement pathways.